Article info

Download PDFPDF

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

Authors

  • Bryan D. Choi Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA Department of NeurosurgeryMassachusetts General Hospital and Harvard Medical School Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Xiaoling Yu Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Ana P. Castano Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Henia Darr CRISPR Therapeutics Cambridge Massachusetts USA PubMed articlesGoogle scholar articles
  • Daniel B. Henderson CRISPR Therapeutics Cambridge Massachusetts USA PubMed articlesGoogle scholar articles
  • Amanda A. Bouffard Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Rebecca C. Larson Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Irene Scarfò Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Stefanie R. Bailey Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Genevieve M. Gerhard Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Matthew J. Frigault Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA Department of MedicineMassachusetts General Hospital and Harvard Medical School Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Mark B. Leick Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Andrea Schmidts Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Jason G. Sagert CRISPR Therapeutics Cambridge Massachusetts USA PubMed articlesGoogle scholar articles
  • William T. Curry Department of NeurosurgeryMassachusetts General Hospital and Harvard Medical School Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Bob S. Carter Department of NeurosurgeryMassachusetts General Hospital and Harvard Medical School Boston Massachusetts USA PubMed articlesGoogle scholar articles
  • Marcela V. Maus Cellular Immunotherapy Program, Cancer CenterMassachusetts General Hospital and Harvard Medical School 149 13th Street, Room 3.216, Charlestown 02129 Boston Massachusetts USA Department of MedicineMassachusetts General Hospital and Harvard Medical School Boston Massachusetts USA PubMed articlesGoogle scholar articles
  1. q 617-726-5619 mvmaus{at}mgh.harvard.edu
View Full Text

Citation

Choi BD, Yu X, Castano AP, et al
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

Publication history

  • Received May 29, 2019
  • Accepted November 6, 2019
  • First published November 14, 2019.
Online issue publication 
November 14, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.